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Human Gastric Mucosa Expresses 
Glandular M3 Subtype of Muscarinic 
Receptors 
A. PFEIFFER, MD, C. HANACK, BA, R. KOPP, MD, R. TACKE, PhD, U. MOSER, PhD, 
E. MUTSCHLER, MD, PhD, G. LAMBRECHT, PhD, and M. HERAWI, MD 
Five subtypes ofmuscarinic receptors have been distinguished by pharmacological and 
molecular biological methods. This report characterizes the muscarinic subtype present 
in human gastric mucosa by radioligand binding studies. The receptor density was 27 
± 6 fmollmg protein and the tritiated ligand N-methylscopolamine had an affinity of 
(Kn) 0.39 ± 0.08 nM (n = 11). The MI receptor selective antagonist pirenzepine and the 
M2 receptor selective ligand AF-DX 116 had low affinities of 148 ± 32 nM (n = 13) and 
4043 ± 1011 nM (n = 3) K n , respectively. The glandular M3 antagonists hexahydrosi-
ladifenidol and silahexocyclium had high affinities ofKn 78 ± 23 nM (n = 5) and 5.6 ± 
1.8 nM (n = 3). The agonist carbachol interacted with a single low-affinity site and 
binding was insensitive to modulation by guanine nucleotides. Antagonist and agonist 
binding studies thus showed an affinity profile typical of M3 receptors of the glandular 
type. 
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Five subtypes of muscarinie receptors are presently 
distinguished based on different primary sequences 
that were derived from cDNA-clones coding for these 
receptors 0-9). Muscarinie receptor heterogeneity 
also has been found by pharmacological methods. MI 
receptors mainly are present on neuronal structures 
and possess a high affinity for pirenzepine (0), telen-
zepine (11), and o-methoxysilahexocyclium (12). M2 
receptors occur in cardiac tissue (13, 14) and in 
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intestinal smooth muscle (15-17). They are character-
ized by a high affinity for ligands like AF-DX 116 (7,8, 
13, 14, 17), and methoctramine (7, 16, 18). M3 recep-
tors (previously termed M2ß) display high affinity for 
silahexocyclium (SiHC) , hexahydrosiladifenidol 
(HHSiD) and related compounds (19, 20, 23) and low 
affinity with AF-DX 116 and methoctramine (7,8, 14, 
18, 22-24). These receptors were identified in glandu-
lar tissue (5, 14, 24) in certain smooth muscle prepa-
rations (15-17, 19, 20, 23-25) and in mucosa from 
porcine stomach (22). 
M3 receptors (26) were shown to activate the 
phosphatidylinositol second messenger system and 
to mediate muscarinic stimulation of acid secretion 
in isolated rat gastric parietal cells (26-29). There 
appear to exist species-specific differences in sub-
types of gastric mucosal muscarinic receptors, as 
rabbits were reported to possess a different subtype 
with low affinity for HHSiD and AF-DX 116 (30). 
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MUSCARINIC M3 RECEPTORS IN HUMAN GASTRIC MUCOSA 
The availability of selective muscarinic antago-
nists opens new therapeutic possibilities, as specific 
types of muscarinic receptors may be blocked with-
out the disadvantage of impeding muscarinic func-
tion in general (24). A first example is the use ofthe 
peripheral MI antagonist pirenzepine in ulcer ther-
apy. HHSiD was suggested to represent a selective 
antispasmodic and antisecretory agent without car-
diac side effects (24). This study was designed 
therefore to characterize the sub type of muscarinic 
receptors occurring in human gastric mucosa by 
radioligand binding studies. 
Experiments were performed using pirenzepine 
to assess the possible presence of MI receptors. To 
further classify the muscarinic receptor subtype 
present, three antagonists that allow a distinction to 
be made between M2 and M3 receptors were tested. 
AF-DX 116 was shown to possess an affinity of 
about 0.1 f.LM for cardiac or M2 receptors while its 
affinity for M3 receptors was 10- to 30-fold lower (7, 
8, 13, 14). HHSiD and SiRe have the inverse 
patterns of affinities with a nanomolar affinity for 
M3 receptors while their affinity for cardiac recep-
tors is 10- to 30-fold lower (7, 8, 19-21, 26). As a 
second approach, the affinity of the muscarinic 
agonist carbachol was determined, which was pre-
viously observed to possess 20- to 100-fold lower 
affinity for M3 as compared to M2 receptors (22, 31, 
32). In addition, binding of carbachol to M3 recep-
tors was insensitive to modulation by guanine nu-
cleotides (22), while a characteristic decrease in 
high-affinity binding, termed GTP-shift, is observed 
with M2 receptors (31, 32). 
MATERIALS AND METHODS 
Drugs. Pirenzepine was kindly supplied by Dr. Ham-
mer, Boehringer Ingelheim, Germany. Hexahydrosi-
ladifenidol (HHSiD) and silahexocydium were synthe-
sized as described (21, 33). AF-DX 116 was a kind gift 
from Dr. A. Zimmer and Dr. G. Trummlitz, Dr. Karl 
Thomae GmbH, Germany. Unlabeled N-methylscopola-
mine (NMS) and carbachol were from Sigma 
(Taufkirchen, Germany). Tris and 5/ -guanylylimido-
diphosphate (GppNHp) were from Boehringer, Mann-
heim, Germany. All other reagents were purchased from 
Merck, Darmstadt, Germany, and were of analytieal 
grade. Tritiated NMS was purchased from Amersham 
International (specific activity 72 Ci/mmol) or from New 
England Nuclear Corporation (specific activity 85 Ci/ 
mmol). 
Tissue preparation. Human gastric fundie mucosa was 
obtained on the occasion of surgery performed because of 
gastric or pancreatic carcinomas or because of recurrent 
ulcer disease. Resected tissue was placed in ice-cold 0.9% 
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saline. The material used was macroscopically intact 
fundic gastric mucosa resected by a pathologist as far as 
possible from a carcinoma. The material was frozen 
within 30-60 min after resection and stored at -800 C. 
The tissue used was fundic mucosa as shown by histo-
logie examination after staining with hematoxylin-eosin. 
Atrophic and markedly gastritie mucosa or tissue show-
ing evidence of infiltration by malignant cells was not 
used. In the case of antrectomies, material dose to the 
proximal margin, whieh contained fundie mucosa, was 
obtained. 
On the day of the experiment, the tissue was thawed on 
iee and subsequent steps were performed at 0_40 C. The 
mucosa was separated from the submucosa by scraping 
with a scalpel blade. The scraping was homogenized in 
0.32 M sucrose, 5 mM Tris HCI, pH 7.5, in a glass-teflon 
Potter Elvehjem with 10 up and down strokes of the 
pestle or with a Polytron Homogenizer at setting 5 for 2 x 
10 sec (Bachhofer, Reutlingen, Germany). The homoge-
nate was filtered through two layers of gauze and then 
centrifuged at 1000 x g for 10 min. The pellet was 
discarded and the supernatant was recentrifuged at 
20,000 g for 20 min. The resulting pellet was resuspended 
in 50 mM Tris HCI buffer, pH 7.4, and used for binding 
assays. 
Binding experiments. Equilibrium binding assays were 
performed by incubation of 0.25 nM tritiated NMS with 
8-12 concentrations of unlabeled ligands and the homog-
f~nate at 220 C for 60 min in a final vol of 1 ml. Duplicates 
or triplicates were performed for each point, which 
differed by less than 10%. Incubations with NMS showed 
that equilibrium was reached after 35 min and remained 
constant for at least 2 hr. The incubations were stopped 
by dilution in ice-cold Tris buffer (50 mM, pH 7.4) to 4 ml 
in order to promote the rapid dissociation of nonspecifi-
cally bound tracer, followed by rapid filtration through 
glass fiber filter disks (Whatman GF-C), which were 
washed with 2 x 5 ml of cold Trisbuffer. Radioactivity 
retained by the filters was determined in aß-counter with 
4 ml liquid scintillation cocktail at a counting efficiency of 
45%. The Lowry method (34) was used for determination 
of pro tein with bovine serum albumin as standard. Atro-
pine (1 fLM) was used to define nonspecific binding, whieh 
was between 10 and 40% of the total tracer bound. 
Data analysis. The unmodified counts were analyzed 
with the Ligand program developed by Munson and 
Rodbard (35) by nonlinear least-squares regression anal-
ysis. Nonspecific binding was treated as a fitted parame-
ter. The best fit model was chosen by using the statisties 
(F test comparing the "goodness of fit" of different 
models tested, see reference 35) implemented in the 
program. Results are expressed as means ± SEM and the 
number of independent experiments (n) is given in the 
text. 
RESULTS 
Muscarinic receptors in human gastric fundic 
mucosa were investigated by displacement of triti-
ated NMS with various unlabeled ligands. NMS 
was chosen as radioactive ligand because of its 
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Fig 1. Displacement curves of tritiated N-methylscopolamine 
(NMS) vs unlabeled NMS or pirenzepine in human gastric 
mucosa. The concentration of [3H1NMS was 0.25 nM corre-
sponding to 18,000 cpm/tube. The data are means from one 
representative experiment performed in triplicate. The variation 
was less than 10%. Protein concentration was 1.5 mg/tube. 
equally high affinity for all known subtypes of 
muscarinic receptors (7). As expected, the displace-
ment curve of unlabeled vs labeled NMS was steep 
and corresponded to a single binding site (Figure 1). 
The affinity of NMS was KD = 0.39 ± 0.08 nM (n = 
11) a~d the binding capacity was 27.7 ± 5.6 fmol/mg 
protem (n = 11). There was no statistically signifi-
cant di~erence between tissue obtained from gas-
trectomles because of carcinomas (n = 7, K D = 0.35 
± 0.11 nM, binding capacity 26.6 ± 5.3 fmol/mg 
pro tein) or antrectomies because of ulcer disease (n 
= 4, K D = 0.44 ± 0.11 nM, binding capacity 27.7 ± 
5.6 fmol/mg protein). 
Pirenzepine was employed to assess whether MI 
receptor subtypes were present. This MI antagonist 
displayed NMS in a steep curve (Figure 1), which 
was best represented by a single binding site. The 
binding affinity of pirenzepine was KD = 148 ± 32 
nM (n = 13) and did not differ between tissues 
obtained from gastrectomies because of carcinomas 
(n = 8, KD = 117 ± 29 nM, binding capacity 28.2 ± 
4.9 fmol/mg protein) or benign diseases (n = 5, KD 
= 198 ± 75 nM, binding capacity 27.3 ± 10.8 
fmol/mg protein). These results suggested the pres-
ence of non-MI receptors. 
Previous experiments had shown that M3 recep-
tors present in porcine gastric mucosa had a low 
affinity for carbachol of about 20 ILM (22). In 
contrast, cardiac or smooth muscle muscarinic re-
c~ptors had a major portion of high-affinity binding 
sItes for carbachol with K D values of 100-300 nM. 
In addition, the mucosal subtype did not show a 
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Fig 2. Displacement of [3H1NMS by the agonist carbachol in the 
absence or presence of 0.1 mM of the hydrolysis-resistant GTP 
analog 5'-guanylylimidodiphosphate (GppNHp) in human gastric 
mucosa. 
decrease in agonist affinity in the presence of gua-
nine nucleotides, while these nucleotides signifi-
cantly decreased agonist bin ding affinity in cardiac 
and smooth muscle homogenates containing pre-
dominantly M2 receptors (22, 31, 32). We therefore 
investigated the properties of human mucosal re-
ceptors using displacement experiments of the ago-
nist carbachol against tritiated NMS in the presence 
or absence of GppNHp, a hydrolysis-resistant ana-
log of the natural guanine nucleotide, GTP. The 
binding affinity of carbachol was 37 ± 17 ILM in the 
absence and 48 ± 19 ILM (n = 6) in the presence of 
0.1 mM of GppNHp, which does not represent a 
statistically significant decrease (Figure 2). The low 
affinity of carbachol was similar to the one observed 
in porcine mucosa (22) or rat gastric parietal cells 
(26). 
A further classification of the muscarinic receptor 
type was achieved by using M2 (AF-DX 116) and 
M3 receptor (HHSiD and SiHC) specific antago-
nists. Each compound displaced NMS completely 
with a steep slope suggestive of a single binding 
component (Figure 3). The affinity of the M3 antag-
onists HHSiD and SiHC was (KD ) 78 ± 23 nM (n = 
5) and 5.6 ± 1.8 nM (n = 3), respectively, and that 
ofthe M2 antagonist AF-DX was (KD ) 4043 ± 1011 
nM (n = 3). There was no evidence for a second 
binding site using either displacer. 
DISCUSSION 
The study classifies muscarinic receptors in hu-
man gastric mucosa by use of selective muscarinic 
antagonists. Pirenzepine, the classical MI antago-
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Fig 3. Displacement of [3HlNMS by the selective antagonists 
hexahydrosiladifenidol (HHSiD), silahexocyclium (SiHC) , and 
AF-DX 116 in human gastric mucosa. 
nist, had a low affinity of less than 100 nM for 
mucosal receptors, which provides no evidence for 
the MI subtype. As the affinity of AF-DX 116 was 
rather low, the presence of cardiac M2 subtypes 
also can be largely exc1uded. 
The M3 antagonist HHSiD had an affinity of 78 
nM for the mucosal receptors. This is at the lower 
end of the range reported for the affinity of HHSiD 
to M3 receptors in glandular tissues (23, 24, 36). 
The affinity of HHSiD was lower than that observed 
previously in rat gastric parietal cell preparations or 
porcine mucosa, which was between 3 and 6 nM 
(22, 26). It therefore appears that species differ-
ences in the affinity of HHSiD to M3 receptors 
exist. This is supported by a study of rabbit parietal 
cells in which the affinity of HHSiD was between 79 
and 211 nM as determined by functional or binding 
assay, respectively (30). Experiments with sila-
hexocyc1ium (SiHC) also showed a high affinity of 
this M3 antagonist, which was 6 nM and thus 
comparable to the affinity of 3 nM KD observed in 
rat gastric parietal cells (26). The very low affinity of 
AF-DX 116 further supports the occurrence of M3 
receptors. The pattern ofligand affinities would also 
fit the M5 receptor recently described by Bonner 
and coworkers (4). However, the mRNA coding for 
this receptor was not found in peripheral tissues (4), 
and therefore it seems unlikely that M5 receptors 
are present in gastric mucosa. However, our tech-
nique does not permit us to exc1ude entirely this 
possibility or the presence of a small population of 
a different subtype of muscarinic receptors. 
In previous experiments carbachol was observed 
to possess a low affinity to rat, dog, or porcine 
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gastric mucosal muscarinic receptors (22, 29, 37, 
38). In contrast to muscarinic receptors in heart and 
gastric smooth musc1e, which display a large de-
crease in high-affinity binding sites in the presence 
of guanine nuc1eotides, gastric mucosal receptors 
were not susceptible to modulation by guanine 
nuc1eotides (22, 38). Similar properties were found 
in human gastric mucosa in this study. In control 
experiments guanine nuc1eotides significantly de-
creased the agonist binding affinity in smooth mus-
c1e (39), which corresponds to observations made in 
porcine and canine gastric smooth musc1e (22, 38). 
In summary, human gastric mucosa was found to 
possess muscarinic receptors that may be c1assified 
as belonging to the M3 subtype. This corresponds 
to the HM4 receptor (5, 6) or the m3 (3, 4, 7) and 
mAChR III (1, 2, 8) as c1assified by the various 
nomenc1atures (9) of the c10ned muscarinic recep-
tors. A major portion of mucosal mucarinic recep-
tors is located on parietal cells (29). It therefore 
seems likely that muscarinic stimulation of acid 
secretion involves M3 receptors in humans, al-
though studies using isolated human parietal cells 
are needed to establish this proposal definitely. 
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